• Viking Therapeutics is drawing fresh attention as a potential acquisition target, centered on its obesity drug candidate VK2735.
• Both injectable and oral forms of VK2735 are in late stage development, making the company a focus for larger pharmaceutical buyers.
• Market speculation has recently pointed to major firms such as Eli Lilly and Pfizer as possible suitors.

For investors tracking NasdaqCM:VKTX, this buyout chatter sits against a mixed share price backdrop. The stock closed at $30.8, with a gain of 8.5% over the past week and a rise of 13.3% over the past year, but it is down 6.0% over the past 30 days and down 13.0% year to date.

The company’s advanced VK2735 program and reported healthy financial position are key reasons it features in acquisition discussions. Any formal move by a larger pharmaceutical group would be a meaningful event for existing shareholders and could influence how the market values obesity drug developers more broadly.

Stay updated on the most important news stories for Viking Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Viking Therapeutics.

Investor Checklist

Quick Assessment

• ✅ Price vs Analyst Target: At US$30.8, the stock trades well below the US$92.33 analyst price target, which is a wide gap to consensus expectations.
• ✅ Simply Wall St Valuation: Simply Wall St currently estimates Viking Therapeutics is trading about 30.3% below its assessed fair value, flagging it as undervalued.
• ❌ Recent Momentum: The share price is down 6.0% over the past 30 days, which shows recent weakness despite the buyout speculation.

There is only one way to know the right time to buy, sell or hold Viking Therapeutics. Head to Simply Wall St's company report for the latest analysis of Viking Therapeutics's Fair Value..

Key Considerations

• 📊 Takeover talk around VK2735 highlights how much of the investment case rests on obesity drug trial outcomes and potential partner or buyer interest.
• 📊 Keep an eye on VK2735 trial readouts, cash burn relative to its loss of US$567.87m and analyst target revisions, as these can quickly shift sentiment.
• ⚠️ The company currently reports no revenue and ongoing losses, so funding needs and execution risk around bringing any product to market remain central concerns.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Viking Therapeutics analysis. Alternatively, you can check out the community page for Viking Therapeutics to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.